| Name | Title | Contact Details |
|---|
Advanced Mobility Systems of Texas is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Propeller is the leading digital platform for respiratory health management.Through sensors, mobile apps and services, Propeller helps reduce the cost of care while delivering better quality of life for individuals with chronic respiratory disease. Backed by Safeguard Scientifics, Social Capital, California HealthCare Foundation and other investors, Propeller Health is now working with organizations like Dignity Health, Wyckoff Heights Medical Center, Amerigroup Florida and the City of Louisville. Company recognition includes TEDMED Innovation Showcase, White House Champion of Change and Bluetooth Breakthrough Product awards. The system has been featured in The Economist, Washington Post, Fast Company, Wired and Scientific American.
Remington Medical Equipment is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.